Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis.

MLA

Li, Sicong, et al. “Cardiovascular Adverse Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib or Imatinib: A Systematic Review, Meta-Analysis and Integrative Bioinformatics Analysis.” Frontiers in Cardiovascular Medicine, vol. 9, Nov. 2022, p. 966182. EBSCOhost, https://doi.org/10.3389/fcvm.2022.966182.

APA

Li, S., He, J., Zhang, X., Cai, Y., Liu, J., Nie, X., & Shi, L. (2022). Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis. Frontiers in Cardiovascular Medicine, 9, 966182. https://doi.org/10.3389/fcvm.2022.966182

Chicago

Li, Sicong, Jinshan He, Xinyi Zhang, Yuchun Cai, Jian Liu, Xiaoyan Nie, and Luwen Shi. 2022. “Cardiovascular Adverse Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib or Imatinib: A Systematic Review, Meta-Analysis and Integrative Bioinformatics Analysis.” Frontiers in Cardiovascular Medicine 9 (November): 966182. doi:10.3389/fcvm.2022.966182.